Business Segments UCB

Stocks

Market Closed - Euronext Bruxelles 18:55:00 07/10/2026 +03			After hours 22:59:56
203.80 ^EUR	+0.74%		203.65	-0.07%

09-30	Merck's experimental skin disease drug succeeds in mid-stage study	RE
09-29	UCB Presents Data From Innovative Myasthenia Gravis Portfolio At AANEM Annual Meeting And MGFA Scientific Session	CI

Breakdown by Business Segment (EUR)

Fiscal Period: December	2021	2022	2023	2024	2025
Pharmaceutical Products
Biopharmaceuticals	5.78B	5.45B	5.18B	6.15B	7.74B
Total Assets	14.21B	15.87B	15.54B	17.35B	18.16B
Interest Expense	-45M	-72M	-144M	-161M	-128M
Income Tax Expense	170M	91M	98M	98M	264M
CAPEX	-493M	-371M	-238M	-234M	-281M
EBT	1.23B	511M	441M	1.16B	1.82B
Gross Profit	4.34B	3.84B	3.54B	4.4B	5.75B
D&A	323M	587M	691M	641M	627M
Operating Income	1.28B	585M	604M	1.32B	1.95B
Net Income	1.06B	418M	343M	1.06B	1.56B

Geographical breakdown of sales (EUR)

Fiscal Period: December	2021	2022	2023	2024	2025
United States	2.89B	2.9B	2.45B	3.04B	4.61B
Total Assets	131M	151M	138M	169M	133M
	-	-	-	-	77M
Other countries	429M	507M	554M	575M	592M
Total Assets	23M	21M	18M	25M	25M
	-	-	-	-	4.61B
Europe -Â Other (Excluding Belgium)	331M	348M	365M	401M	441M
	-	-	-	-	20M
Germany	335M	330M	310M	364M	425M
Total Assets	21M	20M	23M	24M	23M
	-	-	-	-	183M
Japan	561M	324M	269M	257M	315M
Total Assets	25M	19M	17M	17M	18M
	-	-	-	-	94M
Spain	202M	213M	224M	244M	271M
	-	-	-	-	165M
France (Including French Territories)	172M	169M	162M	177M	195M
	-	-	-	-	425M
Italy	159M	154M	143M	171M	183M
	-	-	-	-	271M
U.K. and Ireland	150M	151M	133M	164M	165M
Total Assets	184M	181M	215M	269M	330M
Total Assets	259M	251M	240M	217M	236M
	-	-	-	-	441M
Unallocated	57M	-167M	50M	19M	94M
	-	-	-	-	592M
Belgium	47M	49M	52M	61M	77M
Total Assets	609M	771M	924M	1.03B	1.15B
	-	-	-	-	195M
China	140M	159M	151M	143M	20M
Total Assets	23M	20M	20M	1M	3M
Brazil	-	-	-	-	-
Total Assets	-	-	-	-	-
	-	-	-	-	315M